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Journal of Stroke and CBackground:Hemorrhagic transformation (HT), a complication of ischemic stroke
(IS), might influence patient’s prognosis. Our aim is to evaluate, in a hospital-
based series of patients not treated with thrombolysis, the relationship between
HT and mortality. Methods:We compared mortality of individuals with spontane-
ous HT with that of individuals without. Medical records of patients diagnosed
with anterior IS were retrospectively reviewed. Outcome measures were 30- and
90-day survival after IS onset. Kaplan–Meier estimates were used to construct
survival curves. Cox proportional hazards model was used to estimate hazard ra-
tio (HR) for the main outcome measure (death). HTwas stratified in hemorrhagic
infarction and parenchymal hematoma (PH). We also evaluated the relationship
between HT and the main mortality risk factors (gender, age, premorbid status,
severity of stroke, and radiological features). Results: Thirty days from stroke on-
set, 8.1% (19 of 233) of patients died. At multivariate analysis, PH (HR: 7.7, 95%
confidence interval [CI]: 2.1, 27.8) and low level of consciousness at admission
(HR: 5.0, 95% CI: 1.3, 18.6) were significantly associated with death. At 3-month
follow-up, mortality rate was 12.1% (28 of 232). At multivariate analysis, large
infarct size (HR: 2.7, 95% CI: 1.2, 6.0) and HT (HR: 2.3, 95% CI: 1.0, 5.4) were inde-
pendent risk factors for mortality. Parenchymal hematoma was, however, the
strongest predictor of late mortality (HR: 7.9, 95% CI: 2.9, 21.4). Conclusions: Neu-
rological status and infarct size play a significant role, respectively, in early and late
mortality after IS. Parenchymal hematoma independently predicts both early
and late mortality. Key Words: Ischemic stroke—hemorrhagic transformation—
prognosis—survival—epidemiology.
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Hemorrhagic transformation (HT) is a common compli-
cation of ischemic stroke (IS).1 Overall stroke mortality
has been widely studied.2 Thrombolytic therapy deter-
mines a significant reduction in the proportion of patients
dead or dependent in activities of daily living. This bene-to di Biomedicina Sperimentale e Neuro-
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deaths, with most of the excess of them occurring early
and explained by intracranial hemorrhage.3 Most of the
authors focused their interest on functional outcome of
spontaneous HT,4-6 and it is still uncertain how much
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Table 1. Characteristics of patients by living status at 30 and 90 days from stroke onset
30 d 90 d
Alive (n 5 214) Dead (n 5 19) P Alive (n 5 204) Dead (n 5 19 1 9) P
Age (mean 6 SD) 72.3 6 12.1 77.2 6 8.5 NS 72.1 6 12.2 77.4 6 8.8 .03
Sex (male) 112 (52.3%) 9 (47.4%) NS 107 (52.5%) 13 (46.4%) NS
Previous stroke 68 (31.8%) 4 (21%) NS 65 (31.9%) 7 (25.0%) NS
Hypertension 160 (74.8%) 12 (63.1%) NS 153 (75.0%) 18 (64.3%) NS
Diabetes 79 (36.9%) 5 (26.3%) NS 75 (36.8%) 8 (28.6%) NS
Current smoking 87 (40.6%) 9 (47.4%) NS 84 (41.2%) 11 (39.3%) NS
Cardioembolic stroke 64 (29.9%) 8 (42.1%) NS 60 (29.4%) 12 (42.9%) NS
Severe consciousness impairment 3 (1.4%) 4 (21%) ,.0001 3 (1.5%) 4 (14.3%) .0002
Presence of early CT signs 59 (27.6%) 10 (52.6%) .02 57 (27.9%) 12 (42.9%) NS
Medium/large infarcts 41 (19.1%) 9 (47.4%) .004 36 (17.6%) 13 (46.4%) .0005
HT (HI 1 PH) 23 (10.7%) 6 (31.6%) .008 20 (9.8%) 9 (32.1%) .0008
HI 16 (7.5%) 3 (15.8%) NS 15 (7.4%) 4 (14.3%) NS
PH 7 (3.3%) 3 (15.8%) .01 5 (2.5%) 5 (17.9%) .0002
Abbreviations: CT, computed tomography; HI, hemorrhagic infarction; HT, hemorrhagic transformation; NS, not significant; PH, parenchy-
mal hematoma.
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The current retrospective cohort analysis was designed
to analyze, in a hospital-based series of patients with IS
not treated with recanalization therapy, the association
between HT and mortality.Materials and Methods
All consecutive patients with anterior IS admitted to
our department in the period 2004-2006 were enrolled
in this study. Inclusion criteria have been previously re-
ported.9,10 Briefly, all patients performed a baseline
brain computed tomography (CT) scan within 24 hours
from symptoms onset and a follow-up CT. Patients with
transient ischemic attacks and cerebral hemorrhage
were excluded. If living status was not determinable, pa-
tients were excluded from current analysis.
Early and late mortality were, respectively, defined as
the proportion of patients who died within 30 days and
3months after stroke onset. Data about mortality were ob-
tained from the public record office of the municipality of
Palermo or directly by telephone interview. HTwas strat-
ified in hemorrhagic infarction (HI) and parenchymal he-
matoma (PH).11,12 HI was defined as a petechial infarction
without space-occupying effect, and PH was defined as
a hemorrhage with mass effect.8 Together with HT, the
following risk factors for mortality were investigated:
gender, age, smoking (ever-smokers versus nonsmokers),
previous cerebrovascular accidents (transient ischemic at-
tack, IS, or hemorrhagic stroke), hypertension, diabetes,
cardioembolic origin of stroke (classified according to
the Trial of Org 10172 in Acute Stroke Treatment crite-
ria),13 impairment of consciousness at admission (moder-
ate to severe versus normal to mild impairment), early
CTsigns (hyperdensity of middle cerebral artery, focal hy-podensity consistent with the clinical picture, swelling
because of developing infarction, blurring of gray mat-
ter–white matter distinction), and infarct size (medium–
large infarcts versus small ones).14
The study has been approved by the local ethics
committee.Statistical Analysis
Clinical characteristics of patients dead or alive at
30-day follow-up were compared using c2 test for cate-
gorical variables and t test for continuous variables.
Kaplan–Meier estimates were used to construct survival
curves for early and late mortality. Estimates were calcu-
lated including only those who were still alive at last
follow-up or if dead, whose date of death was known.
The statistical difference between groups was tested
with the log-rank test. Odds ratios, calculated by Cox pro-
portional hazards analysis, were used as measure of asso-
ciation of poor outcome and the variables investigated
(age, gender, clinical characteristics on admission, risk
factors for stroke, CT findings, and HT). Multivariate
analysis included the variables found significantly associ-
ated with death in the univariate analysis. Statistical anal-
ysis was performed using SAS 9.2.
Results
During the study period, 240 patients were included in
the study. All patients received, together with medical
therapies required by concomitant diseases, acetylsali-
cylic acid and subcutaneous heparin at the dosage recom-
mended to prevent deep venous thrombosis. Living
status, 1 month after stroke onset, was available for 233
of the 240 patients initially included in the study
(97.1%), whereas at 3 months, 1 more patient was lost at
Figure 1. Cumulative survival probability of patients stratified by impair-
ment of consciousness, lesion size, and HT. Cumulative survival probability
stratified by (A) impairment of consciousness (gray line5 impairment of con-
sciousness; black line5 no impairment of consciousness); (B) lesion size (gray
line 5 medium/large lesions; black line 5 small lesions); (C) HT (gray
line 5 HT; black line 5 no HT) (P values reported at the left of the vertical
line refer tomortality at 30 days, whereas those at the right of the same line refer
to mortality at 90 days). Abbreviation: HT, hemorrhagic transformation.
PROGNOSIS OF HEMORRHAGIC TRANSFORMATION 651follow-up (232 of 240, 96.7%). HT did not occur in any of
the 8 patients lost at follow-up. At 30 days from stroke on-
set, 19 of 233 patients died (8.1%). No significant differ-
ence was observed for age at admission, gender, and
stroke risk factors between patients who died and those
who were still alive 30 days from stroke onset (Table 1).
Patients who died, compared with those who survived,
had a significantly more severe neurological status, larger
lesions, and more frequently showed early CT signs at
first neuroimaging or HT at a follow-up CT scan
(Table 1). A highly significant difference between strata
was observed when patients were stratified according to
the presence of impairment of consciousness (log-rank
test: c2 12.22; df 1; P , .0005), size of the lesions (log-
rank test: c2 7.09; df 1; P , .008), and the occurrence of
HT (log-rank test: c2 5.56; df 1; P , .02) (Fig. 1). Death,
at multivariate analysis, was significantly associated
only with a more severe neurological deficit at admission
(presence of consciousness impairment). When HT was
stratified in HI and PH, HI was not associated with an in-
creased risk of early mortality, whereas PH was associ-
ated with an almost 8-fold increased risk of death
(Table 2).
At 3-month follow-up, 9 more patients had died (28 of
232, 12.1%). At multivariate analysis, larger lesions and
HTwere independent risk factors for late mortality.Discussion
In our study, overall mortality was of 8.1% at 1 month
after stroke onset and 12.1% at 3-month follow-up. Only
PH and impairment of consciousness were indepen-
dently associated with an increased risk of mortality at
30 days. Ninety days after stroke onset, individuals
with larger lesions or whose IS was complicated by the
occurrence of HT had a significantly increased risk of
death. Neurological status was still associated with
death.
Data on outcome of patients with IS complicated by the
occurrence of HT derive mostly from randomized trials
looking at the efficacy of thrombolysis (Table 3). A recent
analysis identified 16 trials separately reporting data,
both in the treated and in the control group, on fatal intra-
cranial hemorrhage occurring within 7-10 days from
thrombolysis.3 Risk of death for intracranial hemorrhage
was higher in treated patients (4.45%) compared with
controls (.74%), so that most of the excess of early deaths
in patients treated with thrombolysis were attributed to
intracranial hemorrhage.
Thrombolysis, a proven instrument to reduce stroke
severity, influences, in fact, several aspects of stroke espe-
cially the occurrence of HT.
Moreover, results of clinical trials may not be easily
generalized as characteristics of enrolled participants
might be different from patients not enrolled in clinical
trial,15 and therefore, not representative of the general
Table 2. Predictors of early and late mortality: results of univariate and multivariate analysis
30-d mortality 90-d mortality
HR (95% CI) P HRa (95% CI) P HR (95% CI) P HRa (95% CI) P
Age 1.0 (.99, 1.10) NS 1.0 (.97, 1.1) NS 1.05 (1.0, 1.1) .03 1.03 (.99, 1.1) NS
Gender (male) .8 (.3, 2.1) NS — .8 (.3, 1.7) NS
Diabetes .6 (.2, 1.8) NS — .7 (.3, 1.6) NS
Previous stroke .6 (.2, 1.8) NS — .7 (.3, 1.8) NS
Hypertension .6 (.2, 1.5) NS — .6 (.3, 1.4) NS
Cardioembolic stroke 1.7 (.7, 4.2) NS — 1.4 (.7, 3.0) NS
Severe consciousness
impairment
12.0 (3.9, 36.3) ,.0001 5.0 (1.3, 18.8) .01 8.2 (2.8, 23.6) .0001 3.0 (.9, 9.9) NS
Presence of early CT signs 2.7 (1.1, 6.8) .03 1.8 (.7, 4.8) NS 1.8 (.8, 3.7) NS
Medium/large infarcts 3.5 (1.5, 8.7) .006 1.8 (.6, 5.5) NS 3.9 (1.9, 8.0) .0003 2.7 (1.2, 6.0) .02
HT (HI 1 PH) 3.5 (1.3, 9.3) .01 1.8 (.6, 5.5) NS 3.6 (1.6, 7.9) .002 2.3 (1.0, 5.4) .05
No HT Ref. Ref. Ref. Ref.
HI 2.6 (.7, 9.1) NS .8 (.2, 3.2) NS 2.3 (.8, 6.7) NS 1.0 (.3, 3.2) NS
PH 5.6 (1.6, 19.8) .007 7.7 (2.1, 27.8) .002 6.6 (2.5, 17.6) .0002 7.9 (2.9, 21.4) ,.0001
Abbreviations: CT, computed tomography; CI, confidence interval; HI, hemorrhagic infarction; HR, hazard ratio; HRa, HI and PH adjusted
for impairment of consciousness, presence of early CT signs, and lesion size; HT, hemorrhagic transformation; NS, not significant; PH, paren-
chymal hematoma.
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ological studies.
Interesting findings on outcome come also from stroke
registries, where patients are included independently
from specific characteristics and that often incorporate
unbiased data coming both from academic and commu-
nity hospitals and department of neurology and internal
and geriatric medicine.
This is the case of the German Stroke Register Study
Group (ADSR),16 a network of regional hospital-based
stroke register, monitoring quality of stroke care in Ger-
many. The analysis of the ADSR, aimed to investigate pre-
dictors of in-hospital mortality of patients treated
with recombinant tissue plasminogen activator, found
that the occurrence of symptomatic intracranial hemor-
rhage was the second most important complications of
IS predicting early mortality. Patients with symptomatic
intracranial hemorrhage had a significant 8-fold increased
risk of death.
The Nationwide Inpatients Sample has been investi-
gated for mortality risk for the years 1999-2002,17 compar-
ing 2594 patients treated with thrombolysis with 246,370
patients not treated. Although intracerebral hemorrhage
occurred in very small percentage of not treated patients
(.4%), in-hospital fatality rate for intracerebral hemor-
rhage in this group was 25%.
Frequently, prognosis has been investigated pooling to-
gether data on functional outcome and death.
In a small sample of 53 patients with atrial fibrilla-
tion and nonlacunar stroke involving the vascular ter-
ritory of the middle cerebral artery,4 at 3-month
follow-up, severe disability (using a modified Rankin
scale score . 2) and death were not significantly asso-ciated with HT. However, in this series, HT was nearly
2 times more frequent in the group with worst out-
come (38%) compared with those with better outcome
(21%).
A larger hospital-based study,5 including all consecu-
tive patients with IS, reported an overall mortality rate
of 7.3%within 3 months after stroke onset. The authors re-
ported a significant correlation between symptomatic HT
(defined as HT on neuroimaging with any neurological
deterioration) and poor outcome (death and Rankin scale
score . 2) at 3 months (odds ratio: 3.57, 95% confidence
interval: 1.33-9.54).
Similar results were observed in a multicenter prospec-
tive study enrolling 1125 patients with IS.18 Death or dis-
ability (modified Rankin scale score$ 3) was seen in 33 of
the 36 patients with PH (91.7%), 35 of the 98 patients with
HT (57.4%) as compared with 387 of the remaining pa-
tients without HT (37.9%). PH, but not HT overall, was
significantly associated with an increased risk for death
or disability (odds ratio: 15.3, 95% confidence interval:
2.4, 99.4).
More recently, the prospective cohort of the Helsinki
Stroke Thrombolysis Registry was investigated to assess
the impact of symptomatic intracerebral hemorrhage.19
Patients with symptomatic intracerebral hemorrhage
had a significant increased risk of fatal outcome that, ac-
cording to the different definitions used, ranged from
1.5 to 4.8.
In our sample, early and late mortality were related to
PH independently from infarct size and neurological sta-
tus at admission. Although it is predictable that HT of IS
might influence early mortality, it is interesting to note
that still 90 days from stroke onset, individuals who
Table 3. Results from studies reporting data on mortality of hemorrhagic
Reference Patients Treatment Outcome Results
Toni et al7 150 Patients with
supratentorial IS
No thrombolysis; antithrombotic/i.v.
heparin for stroke treatment
By day 30, mortality rate was 16.7%,
whereas 41.3% of patients were
disabled
HT was not related to bad 30-d outcome (OR: .76;
95% CI: .25-2.37)
Fiorelli et al8 609 Patients from
ECASS I trial
307 of 609 patients were treated
with recombinant tPA
At 3-month follow-up, 18.4% of
patients died and 49.3% were
disabled (RS score $ 1)
Only patients with PH2 had a strongly increased
risk of 24-hour deterioration (OR: 32.3, 95%
CI: 13.4-77.7) and 3-month death (OR: 18.0,
95% CI: 8.05-40.1)
Berger et al20 790 Patients from
ECASS II trial
Intravenous thrombolysis (406
patients) versus placebo (384
patients)
Assessment of HT type on clinical
outcome
Only PH2 was associated with an increased risk
for deterioration at 24 hours after stroke onset
(OR: 18; 95%CI: 6-56) and for death at 3 months
(OR: 11; 95% CI: 3.7-36)
Heuschmann16 1658 IS patients from
the German Stroke
Registers Study Group
All patients were treated with tPA In-hospital mortality in patients
with acute IS
ICH occurred in nearly 30% of patients who died,
compared with 4.6% of those who survived
(OR: 8.3, 95% CI: 5.0-13.8)
Hong et al4 1254 Patients with IS Antithrombotic therapy Death within the 3-month period of
follow-up occurred in 91 patients
(7.3%). 34.9% of patients had
a poor outcome at 3 months
(RS score 3-6)
Symptomatic HT was independently associated
with poor outcome (OR: 3.57, 95%
CI: 1.33-9.54)
Paciaroni et al18 1125 Patients with IS 5.8% treated with recombinant tPA At 3 months, 29.2% of patients were
disabled (RS score . 2) and
11.5% died
PH, but not HT, was independently associated
with an increased risk for death or disability
(OR: 15.29, 95% CI: 2.35-99.35)
Goldstein et al21 2362 Patients with
acute IS (retrospective
analysis from database)
311 Patients treated with intravenous
tPA, 72 patients treated with
intra-arterial thrombolysis
Risk of symptomatic HT and
in-hospital mortality
Symptomatic HT was an independent predictor of
in-hospital mortality (OR: 32.6, 95%
CI: 8.8-120.2)
Strbian et al19 985 Patients with
anterior IS
Intravenous thrombolysis Impact of symptomatic ICH on
mortality at 3 months
According to different definitions used risk for
mortality ranged from 1.5 (95% CI 1.0-2.2)
(any ICH) to 4.8 (95% CI 2.8-8.2) (Safe
Implementation of Thrombolysis in Stroke
Registry)
Abbreviations: CI, confidence interval; ECASS, European Cooperative Acute Stroke Study; ICH, intracerebral hemorrhage; IS, ischemic stroke; OR, odds ratio; PH2, parenchymal hematoma type 2;





































M. D’AMELIO ET AL.654experienced PH have a 2-fold increased risk to die com-
pared with those who did not.
Results from clinical trial on recombinant tissue plas-
minogen activator administration in patients with IS
identified PH type 2 as significantly related to an in-
creased risk of 3-month death.8,20 As a consequence,
cerebral hematoma, either of primitive intracerebral
hemorrhage or of HT of IS, seems to play a crucial role
in mortality risk. Our study underlines this association
even in patients treated with conservative therapy (not
thrombolysis).
HT worsen prognosis in patients with IS. In particular,
the occurrence of PH increases the risk of mortality even
in patients not treated with thrombolytic agents.References
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